Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone646-747-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$179.80 million
Profitability
Miscellaneous
Employees483
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions
What is Intercept Pharmaceuticals' stock symbol?
Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."
How were Intercept Pharmaceuticals' earnings last quarter?
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) issued its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($2.28) earnings per share for the quarter, topping the Zacks' consensus estimate of ($2.51) by $0.23. The biopharmaceutical company earned $66.30 million during the quarter, compared to analyst estimates of $58.78 million. Intercept Pharmaceuticals had a negative net margin of 143.57% and a negative return on equity of 534.42%. Intercept Pharmaceuticals's revenue for the quarter was up 52.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.58) earnings per share. View Intercept Pharmaceuticals' Earnings History.
When is Intercept Pharmaceuticals' next earnings date?
What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?
Intercept Pharmaceuticals issued an update on its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $235-245 million, compared to the consensus revenue estimate of $242.29 million.
What price target have analysts set for ICPT?
20 brokers have issued 1 year price targets for Intercept Pharmaceuticals' shares. Their predictions range from $68.00 to $243.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $136.58 in the next year. This suggests a possible upside of 123.1% from the stock's current price. View Analyst Price Targets for Intercept Pharmaceuticals.
What is the consensus analysts' recommendation for Intercept Pharmaceuticals?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intercept Pharmaceuticals.
What are Wall Street analysts saying about Intercept Pharmaceuticals stock?
Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Intercept’s lead drug Ocaliva’s performance has been strong in the year so far. Management’s efforts to increase awareness about the label update of the drug in 2018 and expand sales force across the United States, thereafter, are yielding results. Solid growth in patient enrollment is likely to drive the company’s performance. Meanwhile, Intercept is working to expand the drug’s label in the promising NASH space. While the failure of Gilead’s late-stage study on selonsertib in patients suffering from compensated cirrhosis due to NASH puts Intercept ahead in the race, additional results from the REGENERATE study in NASH were mixed and did not impress investors. Nevertheless, a potential approval in this indication will significantly boost growth. However, shares have underperformed the industry in the year so far." (10/14/2019)
- 2. Stifel Nicolaus analysts commented, "We are reiterating our Hold rating on ICPT after the company reported a slight 2Q19 beat on Ocaliva revenues, which appear to have been aided by a benefit in channel inventories. With that said, our thesis remains unchanged and we think there are too many unknown variables in terms of OCA’s potential adcom/approval and launch in NASH for us to be comfortable recommending the stock here. Management remains on track to file its NDA for OCA in NASH by the end of this quarter followed by its MAA filing in the EU in 4Q19. We think investor focus remains on the potential for OCA in NASH and in particular: whether or not ICPT’s filing of a NDA for OCA in NASH (rather than a sNDA) can lead to bi- furcated/indication based pricing, potential payer/reimbursement dynamics in the NASH category and the use of non-invasive biomarkers vs. biopsy for diagnosis." (8/12/2019)
- 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $170 PT. Positive Ph3 data on fibrosis de-risk this binary readout. Intercept announced this morning that the 25mg dose hit on one of the key endpoints, which is a one point change in fibrosis stage (OCA 23.1%, placebo 11.9%, p-value=0.0002). They saw a numerical trend on NASH resolution in the 25mg. Although this endpoint did not hit (25mg p-value=0.1268), we believe that the data profile for OCA will support approval; fibrosis is relevant for potential liver outcomes. Since there was a p-value of 0.0013 when F1 co-morbidities were added, we are interested to see more analysis around NASH resolution." (2/19/2019)
Has Intercept Pharmaceuticals been receiving favorable news coverage?
News coverage about ICPT stock has trended negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Intercept Pharmaceuticals earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Intercept Pharmaceuticals.
Are investors shorting Intercept Pharmaceuticals?
Intercept Pharmaceuticals saw a increase in short interest in September. As of September 30th, there was short interest totalling 5,730,000 shares, an increase of 5.5% from the August 30th total of 5,430,000 shares. Based on an average trading volume of 576,800 shares, the days-to-cover ratio is presently 9.9 days. Currently, 22.8% of the shares of the stock are short sold. View Intercept Pharmaceuticals' Current Options Chain.
Who are some of Intercept Pharmaceuticals' key competitors?
Some companies that are related to Intercept Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Perrigo (PRGO), Catalent (CTLT), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Beigene (BGNE), Amarin (AMRN), Horizon Therapeutics (HZNP), The Medicines (MDCO), Ascendis Pharma A/S (ASND) and United Therapeutics (UTHR).
What other stocks do shareholders of Intercept Pharmaceuticals own?
Who are Intercept Pharmaceuticals' key executives?
Intercept Pharmaceuticals' management team includes the folowing people:
- Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 51)
- Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 49)
- Mr. Jerome B. Durso, Chief Operating Officer (Age 51)
- Mr. Ryan T. Sullivan, Gen. Counsel & Sec. (Age 43)
- Dr. Gail Cawkwell, Sr. VP of Medical Affairs, Safety & Pharmacovigilance (Age 57)
Who are Intercept Pharmaceuticals' major shareholders?
Intercept Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Larson Financial Group LLC (0.00%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, David A Ford, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Luca Benatti, Mark Pruzanski, Paolo Fundaro, SPA Genextra and Srinivas Akkaraju. View Institutional Ownership Trends for Intercept Pharmaceuticals.
Which institutional investors are buying Intercept Pharmaceuticals stock?
ICPT stock was acquired by a variety of institutional investors in the last quarter, including Larson Financial Group LLC. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener, Luca Benatti, Mark Pruzanski and Srinivas Akkaraju. View Insider Buying and Selling for Intercept Pharmaceuticals.
How do I buy shares of Intercept Pharmaceuticals?
Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Intercept Pharmaceuticals' stock price today?
One share of ICPT stock can currently be purchased for approximately $61.21.
How big of a company is Intercept Pharmaceuticals?
Intercept Pharmaceuticals has a market capitalization of $2.00 billion and generates $179.80 million in revenue each year. The biopharmaceutical company earns $-309,240,000.00 in net income (profit) each year or ($10.86) on an earnings per share basis. Intercept Pharmaceuticals employs 483 workers across the globe.View Additional Information About Intercept Pharmaceuticals.
What is Intercept Pharmaceuticals' official website?
How can I contact Intercept Pharmaceuticals?
Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]
MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
